Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma.

Hidalgo-Soto M, Rodríguez-Lobato LG, Motlló Borrella C, Sánchez Cayuela Á, Lopez Pardo J, Rosiñol L, Cibeira MT, García-Guiñon A, Tolosa-Ridao C, Carro Arostegui I, Sureda A, Herranz MJ, Abella Montreal E, Pelicano M, Barrau Alzuria Y, Cortes Sansa M, Gironella M, González Y, Fernández De Larrea C

Open source

DOI: 10.1111/ejh.70126
Published: 2026 Jun
Container: European journal of haematology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/ejh.70126,
  title = {Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma.},
  author = {Hidalgo-Soto M and Rodríguez-Lobato LG and Motlló Borrella C and Sánchez Cayuela Á and Lopez Pardo J and Rosiñol L and Cibeira MT and García-Guiñon A and Tolosa-Ridao C and Carro Arostegui I and Sureda A and Herranz MJ and Abella Montreal E and Pelicano M and Barrau Alzuria Y and Cortes Sansa M and Gironella M and González Y and Fernández De Larrea C},
  year = {2026},
  journal = {European journal of haematology},
  doi = {10.1111/ejh.70126},
  url = {https://doi.org/10.1111/ejh.70126}
}

RIS

TY  - JOUR
TI  - Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma.
AU  - Hidalgo-Soto M
AU  - Rodríguez-Lobato LG
AU  - Motlló Borrella C
AU  - Sánchez Cayuela Á
AU  - Lopez Pardo J
AU  - Rosiñol L
AU  - Cibeira MT
AU  - García-Guiñon A
AU  - Tolosa-Ridao C
AU  - Carro Arostegui I
AU  - Sureda A
AU  - Herranz MJ
AU  - Abella Montreal E
AU  - Pelicano M
AU  - Barrau Alzuria Y
AU  - Cortes Sansa M
AU  - Gironella M
AU  - González Y
AU  - Fernández De Larrea C
PY  - 2026
JO  - European journal of haematology
DO  - 10.1111/ejh.70126
UR  - https://doi.org/10.1111/ejh.70126
ER  -

APA

M, H., LG, R., C, M. B., Á, S. C., J, L. P., L, R., MT, C., A, G., C, T., I, C. A., A, S., MJ, H., E, A. M., M, P., Y, B. A., M, C. S., M, G., Y, G., & C, F. D. L. (2026). Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma.. European journal of haematology. https://doi.org/10.1111/ejh.70126

Source records

pubmed · retrieved 2026-09-25T07:59:26.974Z